• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccina

tetano

Editor, Senior Moderator
Cell Rep


. 2024 Nov 5;43(11):114922.
doi: 10.1016/j.celrep.2024.114922. Online ahead of print. Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination

Jordan J Clark[SUP] 1 [/SUP], Irene Hoxie[SUP] 1 [/SUP], Daniel C Adelsberg[SUP] 2 [/SUP], Iden A Sapse[SUP] 2 [/SUP], Robert Andreata-Santos[SUP] 3 [/SUP], Jeremy S Yong[SUP] 1 [/SUP], Fatima Amanat[SUP] 2 [/SUP], Johnstone Tcheou[SUP] 1 [/SUP], Ariel Raskin[SUP] 1 [/SUP], Gagandeep Singh[SUP] 1 [/SUP], Irene González-Domínguez[SUP] 2 [/SUP], Julia E Edgar[SUP] 4 [/SUP], Stylianos Bournazos[SUP] 4 [/SUP], Weina Sun[SUP] 2 [/SUP], Juan Manuel Carreño[SUP] 1 [/SUP], Viviana Simon[SUP] 5 [/SUP], Ali H Ellebedy[SUP] 6 [/SUP], Goran Bajic[SUP] 2 [/SUP], Florian Krammer[SUP] 7 [/SUP]



Affiliations
Free article Abstract

Neutralizing antibodies correlate with protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent studies, however, show that binding antibody titers, in the absence of robust neutralizing activity, also correlate with protection against disease progression. Non-neutralizing antibodies cannot directly protect against infection but may recruit effector cells and thus contribute to the clearance of infected cells. Additionally, they often bind conserved epitopes across multiple variants. Here, we characterize 42 human monoclonal antibodies (mAbs) from coronavirus disease 2019 (COVID-19)-vaccinated individuals. Most of these antibodies exhibit no neutralizing activity in vitro, but several non-neutralizing antibodies provide protection against lethal challenge with SARS-CoV-2 in different animal models. A subset of those mAbs shows a clear dependence on Fc-mediated effector functions. We have determined the structures of three non-neutralizing antibodies, with two targeting the receptor-binding domain and one that binds the subdomain 1 region. Our data confirm the real-world observation in humans that non-neutralizing antibodies to SARS-CoV-2 can be protective.

Keywords: ADCC; ADCP; CP: Immunology; effector functions; immunology; mAbs; non-neutralizing mAbs; spike.

 
Back
Top Bottom